ENDRA Life Sciences Inc. (NDRA) stock
NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$4.04+0.12 (+2.93%)
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
ENDRA Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
ENDRA Life Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.95M, down 16.7% year over year. For fiscal 2025 it was $1.85M, down 42.0% from the year before. The highest annual figure on record is $6.57M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85M | -42.0% |
| FY2024 | Dec 31, 2024 | $3.19M | -36.2% |
| FY2023 | Dec 31, 2023 | $5.00M | -23.7% |
| FY2022 | Dec 31, 2022 | $6.55M | +19.5% |
| FY2021 | Dec 31, 2021 | $5.48M | -7.4% |
| FY2020 | Dec 31, 2020 | $5.92M | -10.0% |
| FY2019 | Dec 31, 2019 | $6.57M | +39.2% |
| FY2018 | Dec 31, 2018 | $4.72M | +144.6% |
| FY2017 | Dec 31, 2017 | $1.93M | +289.8% |
| FY2016 | Dec 31, 2016 | $495.38K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $233.67K | -38.7% |
| Q1 FY2026 | Mar 31, 2026 | $776.41K | +46.9% |
| Q4 FY2025 | Dec 31, 2025 | $508.14K | -20.3% |
| Q3 FY2025 | Sep 30, 2025 | $432.11K | -45.6% |
| Q2 FY2025 | Jun 30, 2025 | $381.06K | -46.8% |
| Q1 FY2025 | Mar 31, 2025 | $528.69K | -49.2% |
| Q4 FY2024 | Dec 31, 2024 | $637.96K | +10.1% |
| Q3 FY2024 | Sep 30, 2024 | $794.44K | -51.3% |
| Q2 FY2024 | Jun 30, 2024 | $716.37K | -48.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.04M | -25.1% |
| Q4 FY2023 | Dec 31, 2023 | $579.35K | -65.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.63M | -10.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.40M | -24.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.39M | +14.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.66M | +16.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.83M | +56.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.85M | +5.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.21M | +6.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.42M | +24.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.17M | -33.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.74M | +17.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.14M | -24.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.14M | -43.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.77M | +20.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.49M | +14.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.52M | -14.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.03M | +93.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.47M | +26.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.30M | +55.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.77M | +6.3% |
| Q4 FY2018 | Dec 31, 2018 | $1.05M | -22.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.16M | +287.0% |
| Q2 FY2018 | Jun 30, 2018 | $839.76K | +380.6% |
| Q1 FY2018 | Mar 31, 2018 | $1.67M | +1641.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.36M | +755.6% |
| Q3 FY2017 | Sep 30, 2017 | $300.53K | +118.5% |
| Q2 FY2017 | Jun 30, 2017 | $174.73K | – |
| Q1 FY2017 | Mar 31, 2017 | $95.81K | – |
| Q4 FY2016 | Dec 31, 2016 | $158.96K | – |
| Q3 FY2016 | Sep 30, 2016 | $137.54K | – |
See a number that looks wrong?